CEO updates regulatory progress of lead ADHD asset CTx-1301
Chairman and CEO Shane Schaffer discussed the FDA Complete Response timeline and commercialization strategy for CTx-1301 in an interview. The company continues to prepare commercialization plans for its lead product.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed